AlphaRx To Present GAI-122 and Zysolin Pre-Clinical Study Data At AAPS Annual Meeting

HONG KONG, Nov. 16 /PRNewswire-FirstCall/ - AlphaRx, Inc. (OTCBB: ALRX) is pleased to announce that Dr. Joseph Schwarz, Chief Scientist of the Company will present GAI-122 and Zysolin™ development program through two poster presentations at the American Association of Pharmaceutical Scientists annual meeting held in New Orleans from November 14th to November 18th, 2010.

About GAI-122

GAI-122, an investigational, injectable nanoemulsion of a Mitochondria-targeted neuroprotective agent formulated with AlphaRx's proprietary drug delivery technology, and has been shown to provide significant neuroprotection in multiple in vitro and in vivo animal studies, suggesting that this injectable nanoemulsion formulation has the potential to effectively treat patients with acute ischemic stroke or to prevent postoperative delirium. Mitochondria are intracellular structures that are responsible for generating energy within all cells and play an important role in mediating brain cell function and survival. Mitochondrial dysfunction has been linked to Stroke, Alzheimer's and Huntington's diseases. It is thought that GAI-122 facilitates Adenosine Triphosphate (ATP) production, protecting cell membranes and mitochondria from oxidative damage and, in particular, brain mitochondria from swelling.

About Zysolin™

Zysolin™ is a Tobramycin compound, encapsulated in AlphaRx's Nano Drug Delivery Platform, intended for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically ventilated patients. Zysolin™ improves the intracellular activity of Tobramycin - in layman's term, increasing the drug concentration of Tobramycin inside human macrophages, thus improving its antibacterial activity against intracellular Klebsiella, Pseudomondas aeruginosa and Staphylococcus bacterial strains in pneumonia patients. The active ingredient in Zysolin™, Tobramycin, has a longstanding and proven clinical treatment record. Delivered by inhalation, using proprietary nanotechnology developed by AlphaRx, the company believes Zysolin™ will have an attractive safety, tolerability and efficacy profile when compared to injectible Tobramycin.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development. The Company's product candidates address various pharmaceutical markets, including inflammation, stroke and pneumonia.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.

      

SOURCE AlphaRx Inc.

 

CONTACT:

Michael Lee
President & CEO
AlphaRx Inc.
Web:http://www.AlphaRx.com">www.AlphaRx.com
Email:  

mailto:info@AlphaRx.com info@AlphaRx.com

Ticker Symbol: (NASDAQ-OTCBB:ALRX)

Terms and conditions of use apply
Copyright © 2010 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: November 2010

View comments

Hide
(web3)